Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
898results about "Fusions for plasma life prolonging" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
ActiveUS8124084B2Extended half-lifeImprove bioavailabilityPeptide/protein ingredientsAntibody mimetics/scaffoldsBiological bodyVaccination
The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.
Owner:UNIV OF CONNECTICUT
Serum albumin binding proteins with long half-lives
InactiveUS20070269422A1Increased serum half-lifeReduce dosing frequencyOrganic active ingredientsPeptide/protein ingredientsSerum igePrimate
The present invention relates to amino acid sequences that are capable of binding to serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides. Particularly, the amino acid sequences and compounds of the present invention bind to or otherwise associate with serum albumin in such a way that, when the amino acid sequence or compound is bound to or otherwise associated with a serum albumin molecule in a primate, it exhibits a serum half-life of at least 50% of the natural half-life of serum albumin in said primate.
Owner:ABLYNX NV
Modified antibody compositions, methods of making and using thereof
InactiveUS20100189651A1Reduce capacityNervous disorderAntibody mimetics/scaffoldsAntibody fragmentsChemistry
The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
Owner:CYTOMX THERAPEUTICS
CTLA4-Ig immunoadhesins
Owner:XENCOR INC
Activin-ActRII antagonists and uses for increasing red blood cell levels
ActiveUS20090047281A1Easy to produceReduce expressionCompound screeningApoptosis detectionPrimateRed Cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Pegylated interleukin-10
InactiveUS7052686B2Minimize disruptionPeptide/protein ingredientsAntipyreticInterleukin 10White blood cell
Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10.
Owner:MERCK SHARP & DOHME CORP
Compositions and Methods for Immunomodulation in an Organism
ActiveUS20120177598A1Long half-lifeGood treatment effectPolypeptide with localisation/targeting motifPeptide/protein ingredientsVaccinationHalf-life
The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.
Owner:UNIV OF CONNECTICUT
Modified Antibody Compositions, Methods of Making and Using Thereof
The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
Owner:CYTOMX THERAPEUTICS
Activin-actrii antagonists and uses for increasing red blood cell levels
ActiveUS20090163417A1Reduce expressionIncrease redCompound screeningApoptosis detectionPrimateRed Cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Therapeutic agents comprising elastin-like peptides
ActiveUS20100022455A1Enhanced advantageImprove stabilityBacteriaPeptide/protein ingredientsSolubilityTherapeutic protein
The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII / VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and / or persistance in the body, solubility, and bioavailability.
Owner:DUKE UNIV
Long-acting coagulation factors and methods of producing same
ActiveUS20130243747A1Prevent coagulationPreventing hemophiliaBacteriaPeptide/protein ingredientsNucleotidePolynucleotide
Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
Owner:OPKO BIOLOGICS
Antagonists of activin-actriia and uses for increasing red blood cell levels
ActiveUS20100028331A1Easy to produceReduce expressionPeptide/protein ingredientsAntibody mimetics/scaffoldsPrimateRed Cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Antagonists of actriib and uses for increasing red blood cell levels
InactiveUS20100028332A1Distribution moreMany formatsPeptide/protein ingredientsAntibody mimetics/scaffoldsRed CellAntagonist
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Pegylated interleukin-10
InactiveUS20060210534A1Minimize disruptionPeptide/protein ingredientsAntipyreticInterleukin 10White blood cell
Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10.
Owner:SCHERING CORP
Long-acting polypeptides and methods of producing and administering same
ActiveUS20130184207A1Reduce dosing frequencyIncrease the areaPeptide/protein ingredientsAntibody mimetics/scaffoldsNucleotideChorionic gonadotrophin
A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
Owner:OPKO BIOLOGICS
Albumin fusion proteins
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
Owner:HUMAN GENOME SCI INC
Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
ActiveUS8178495B2Improve stabilityImprove solubilityBacteriaPeptide/protein ingredientsSolubilityTherapeutic protein
The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII / VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and / or persistance in the body, solubility, and bioavailability.
Owner:DUKE UNIV
Long-acting coagulation factors and methods of producing same
ActiveUS20100317585A1Improving biological half lifeImproving area under curve （AUC）Peptide/protein ingredientsAntibody mimetics/scaffoldsNucleotideChorionic gonadotrophin
Polypeptides and polynucleotides encoding same comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a coagulation factor and not to an amino terminus are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using same are also disclosed.
Owner:OPKO BIOLOGICS
Apolipoprotein analogues
InactiveUS20020156007A1Antibody mimetics/scaffoldsGenetic material ingredientsCubilinLipid formation
The invention relates to a pharmaceutical composition comprising an apolipoprotein construct, to an apolipoprotein construct, a nucleic acid sequence encoding the apolipoprotein construct, a vector comprising the nucleic acid sequence, a method for producing the apolipoprotein construct, and a method of treatment comprising administering the apolipoprotein construct. The presented data document that the constructs according to the invention are capable of binding lipids, are capable of binding cubilin, which is a strong Apo Al receptor, stronger than native Apo A-I and that the plasma half life of the constructs is at least tripled compared to native Apo A-I. Together these data document that the constructs according to the invention are strong candidates for treatment of cardiovascular diseases.
Owner:F HOFFMANN LA ROCHE & CO AG
Bispecific binding molecules for Anti-angiogenesis therapy
InactiveUS20110172398A1Reduce manufacturing costImproving desired propertySenses disorderSugar derivativesAngiogenesis EffectAntiangiogenic therapy
Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a Dll4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and Dll4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same.
Owner:BOEHRINGER INGELHEIM INT GMBH
Serum albumin binding proteins with long half-lives
InactiveUS20100113339A1Increased serum half-lifeReduce dosing frequencyNervous disorderPeptide/protein ingredientsHalf-lifeSerum albumin
The present invention relates to amino acid sequences that are capable of binding to serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.
Owner:ABLYNX NV
Factor IX Polypeptides and Methods of Use Thereof
Owner:BIOVERATIV THERAPEUTICS INC
Modified annexin proteins and methods for preventing thrombosis
InactiveUS20050222030A1Inhibition of attachmentReducing endothelial cell damagePeptide/protein ingredientsAntibody mimetics/scaffoldsTreatment effectSufficient time
A modified annexin protein, preferably annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation. It does not, however, affect platelet aggregation necessary for hemostasis. The modified annexin molecule can be a homodimer of annexin, an annexin molecule coupled to one or more polyethylene glycol chains, or an annexin molecule coupled to another protein. By increasing the molecular weight of annexin, the modified annexin is made to remain in circulation for sufficient time to provide a sustained therapeutic effect.
Owner:ALAVITA PHARMA
Methods and compositions for delivering active agents with enhanced pharmacological properties
InactiveUS20130172274A1Good curative effectImprove efficacyOrganic active ingredientsPeptide/protein ingredientsActive agentIn vivo
Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.
Owner:DUKE UNIV
Antagonists of activin-actriia and uses for increasing red blood cell levels
ActiveUS8895016B2Reduce expressionIncrease red blood cell and hemoglobin levelPeptide/protein ingredientsAntibody mimetics/scaffoldsPrimateRed blood cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Long-acting coagulation factors and methods of producing same
Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
Owner:OPKO BIOLOGICS
Modifications of peptide compositions to increase stability and delivery efficiency
ActiveUS8067532B2Increased stability and potencyReduce probabilityPeptide/protein ingredientsTransferasesPhysical stabilityDisulfide bond
The disclosed invention relates to methods of modifying peptide compositions to increase stability and delivery efficiency. Specifically, the disclosed invention relates to methods to increase the stability and delivery efficiency of protein kinase C (PKC) modulatory peptide compositions. A “therapeutic peptide composition” comprises a “carrier peptide” and a “cargo peptide.” A “carrier peptide” is a peptide or amino acid sequence within a peptide that facilitates the cellular uptake of the therapeutic peptide composition. The “cargo peptide” is a PKC modulatory peptide. Peptide modifications to either the carrier peptide, the cargo peptide, or both, which are described herein increase the stability and delivery efficiency of therapeutic peptide compositions by reducing disulfide bond exchange, physical stability, reducing proteolytic degradation, and increasing efficiency of cellular uptake.
Owner:KAI PHARMA
Antagonists of actriib and uses for increasing red blood cell levels
InactiveUS20120003218A1Distribution moreMany formatsHormone peptidesPeptide/protein ingredientsPrimateRed Cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Factor viii chimeric and hybrid polypeptides, and methods of use thereof
ActiveUS20140294821A1Evaluating efficacyEvaluate FVIIIFc consumptionFactor VIIPeptide/protein ingredientsNucleotidePolynucleotide
The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells
Owner:BIOVERATIV THERAPEUTICS INC
Long-acting polypeptides and methods of producing same
ActiveUS20070190611A1Reduce morbidityProlong lifePeptide/protein ingredientsAntibody mimetics/scaffoldsNucleotideChorionic gonadotrophin
A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a peptide-of-interest are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
Owner:OPKO BIOLOGICS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com